Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + dd-TMZ in Recurrent Gliomas
NCT06258018Phase 2Not yet recruiting
- Sponsor
- Armando Santoro
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in glioblastoma (GBM), malignant glioma, sponsored by Armando Santoro. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT06258018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258018.